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Abstract Anticoagulants remain the primary strategy for
the prevention and treatment of thrombosis. Unfractionated
heparin, low molecular weight heparin, fondaparinux, and
warfarin have been studied and employed extensively with
direct thrombin inhibitors typically reserved for patients
with complications or those requiring intervention. Novel
oral anticoagulants have emerged from clinical develop-
ment and are expected to replace older agents with their
ease of use and more favorable pharmacodynamic profiles.
Hemorrhage is the main concerning adverse event with all
anticoagulants. With their ubiquitous use, it becomes
important for clinicians to have a sound understanding of
anticoagulant pharmacology, dosing, and toxicity.
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Introduction
Anticoagulants are the cornerstone therapy for thrombosis
prevention and treatment. While anticoagulants are com-
monly employed, their use is often associated with adverse
drug events and increased readmission rates. In older patients
presenting to an Emergency Department with a warfarin
adverse drug event, about half required hospitalization [1].
Despite novel anticoagulants being touted as replacements
for warfarin and heparin products, rivaroxaban has been
associated with serious thrombotic events while dabigatran
has been associated with serious bleeding [2, 3]. Since
anticoagulant use enhances the risk for Emergency Depart-
ment visits by as much as 35-fold [4], clinicians must be
familiar with anticoagulants, their pharmacological proper-
ties, pharmacodynamics, dosing, monitoring, and toxicity.
Pathophysiology
The coagulation cascade is triggered by tissue factor release
from tissue trauma or vascular injury (Fig. 1) [5]. Tissue
factor forms a complex with factor VIIa in the presence of
calcium and cleaves clotting factors X and IX to their acti-
vated forms (factors Xa and IXa). The prothrombinase
complex is then assembled on a phospholipid membrane and
cleaves prothrombin (factor II) to factor IIa (thrombin).
Thrombin is one of the most potent activators of primary
(platelet-mediated) and secondary (clotting factor-medi-
ated) hemostasis. Thrombin may also potentiate clot for-
mation by fibrin polymerization, platelet receptor activation,
endothelium activation, and activation of factors V, VIII, XI,
and XIII. Anticoagulant agents can inhibit thrombogenesis
by altering various pathways within the clotting cascade or
by targeting thrombin directly, attenuating thrombin gener-
ation. Indirect inhibitors, however, target and bind to natu-
rally occurring plasma cofactors, such as antithrombin (AT),
catalyzing their interaction with clotting enzymes [5].
Pharmacology of Heparins and Fondaparinux
Unfractionated heparin (UFH) and low molecular weight
heparin (LMWH) are the anticoagulants of choice in
acute thrombosis due to their rapid onset of
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antithrombotic activity. Since heparins are dependent on
the presence of AT for clotting factor inhibition, they are
considered indirect anticoagulants (Table 1) [6••, 7, 8].
Heparins have no fibrinolytic activity and will not lyse
existing thrombi. Heparins contain an active pentasac-
charide sequence that binds to AT. Once heparin binds
and activates AT, it can readily dissociate and bind to
additional AT, providing a continuous anticoagulant
effect. This binding produces a conformational change,
accelerating AT binding and inactivation of coagulation
factors XIIa, IXa, XIa, Xa and thrombin. The active
pentasaccharide sequence responsible for catalyzing AT is
found on one-third and one-fifth of the chains of UFH and
LMWH, respectively. Fondaparinux is a synthetic analog
of the naturally occurring pentasaccharide found in hep-
arins [6••, 7, 8]. Fondaparinux selectively and irreversibly
binds to AT. This results in neutralization of factor Xa,




Intravenous (IV) infusion or subcutaneous injections are
the available routes for UFH administration and IV is
preferred [6••, 7–9]. When given via subcutaneous injec-
tion for therapeutic anticoagulation, doses need to be large
enough ([30,000 U/day) to overcome UFHs low bio-
availability. UFH readily binds to plasma proteins, which
contributes to its variable anticoagulant response after
parenteral administration. Despite these limitations IV
administration rapidly achieves therapeutic plasma con-
centrations that can be effectively monitored and adjusted
based on infusion rates [7].
UFH clearance from the systemic circulation is dose-
related and occurs through two independent mechanisms
[6••, 8]. The initial phase is the rapid and saturable binding
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Fig. 1 The coagulation cascade is comprised of the intrinsic (contact
activation) pathway and the extrinsic (tissue factor) pathway. Each
pathway generates a series of reactions in which inactive circulating
enzymes and their co-factors are activated. These activated factors
then catalyze the next reactions in the cascade. Thrombin plays a
pivotal role by triggering the conversion of soluble fibrinogen to
insoluble fibrin monomers, which serve as the foundation for
thrombus formation. Thrombin also activates factors VIII, V, and
XIII. Factor XIII generates the covalent bonds that link fibrin strands
ensuring structural integrity. Anticoagulants, either through their
interaction with Antithrombin (AT) or through a direct inhibition of
thrombin, interrupt these enzymatic reactions
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UFH is depolymerized. The second phase is a slower, non-
saturable, renal-mediated clearance. At therapeutic doses,
UFH is cleared primarily via depolymerization, with the
higher molecular weight chains being cleared more rapidly
than lower weight counterparts. As clearance becomes
dependant on the kidney, increased or prolonged UFH
dosing provides a disproportionate increase in both the
intensity and the duration of the anticoagulant effect.
The anticoagulant response to UFH administration is
monitored using the activated partial thromboplastin time
(aPTT). The aPTT should be measured every 6 h with IV
administration, and doses adjusted accordingly, until the
patient has sustainable therapeutic levels. Once steady state is
reached the frequency of monitoring can be extended [8, 10].
To overcome variables delivering UFH, weight-based
dosing nomograms are recommended for treatment of
thromboembolic disease. Dosing nomograms have been
associated with significantly higher initial UFH doses,
shorter time to therapeutic activated aPTT, and no increase
in bleeding events. UFH dosing nomograms will differ
from hospital to hospital due to differences in thrombo-
plastin agents and inter-laboratory standardizations in
aPTT measurements [10].
Clinical Indications
Clinical indications for UFH include treatment of acute
coronary syndromes (ACS), treatment or prevention of
venous thromboembolism (VTE), bridge therapy for atrial
fibrillation (AF), and cardioversion (Table 2) [6••, 11–13].
UFH utilization has diminished with LMWH and fonda-
parinux availability and their superior pharmacokinetic
profiles [6••, 7]. UFH, with a short half-life and reversal
capability, remains the best option in patients requiring
higher UFH doses, in patients with underlying bleeding
risk, or in those critically ill with organ dysfunction.
Patients with fluctuating renal function or with a creatinine
clearance less than 30 mL/min are not candidates for
LMWH or fondaparinux due to the risk of accumulation
and increased bleeding risk [14]. When used for throm-
boprophylaxis in medical patients, three times daily UFH
dosing provides better efficacy in preventing VTE events
compared to twice daily dosing but generates more major
bleeding episodes [15].
Complications and Reversal of Effect
The major complications of UFH therapy include bleeding
(major bleeding, 0–7 %; fatal bleeding, 0–3 %) and hepa-
rin-induced thrombocytopenia (HIT, 1–5 %). Patients
receiving UFH for periods of more than 1 month are also at
an increased risk for osteoporosis and development of
vertebral fractures (approximately 2 % incidence) [16].
Hemorrhagic episodes are associated with the intensity of
anticoagulation, route of administration (continuous infu-
sions are associated with lower rates), and concomitant use
of glycoprotein (gp) IIB/IIIA inhibitors, aspirin or fibri-
nolytic therapy [16–18]. The relationship between supra-
therapeutic levels of UFH (elevated aPTT, heparin levels or
anti-Xa levels) and major bleeding is not well established
and has not been prospectively compared in clinical trials.
Major bleeding can occur within therapeutic levels of
anticoagulation. Patient-specific risk factors are the most
important consideration when determining the bleeding
risk, including: age, gender, renal failure, low body weight,
and excessive alcohol consumption [16–18].
Anticoagulation management before and after surgery is
a patient specific, risk versus benefit decision. It is based on
the procedure and patient’s risk factors for bleeding and
thrombosis. For patients requiring peri-operative antico-
agulation in elective procedures or surgery, discontinuing
therapeutic IV UFH doses 4 h prior to the procedure and
measuring an aPTT is usually sufficient, as normal
hemostasis is restored in this time frame in most cases. If
the aPTT remains elevated, then hourly measurements are
advised until the aPTT returns to baseline [19–21]. Ther-
apeutic UFH therapy can be restarted 12 h after major
surgery, but should be delayed longer for evidence of
continued bleeding. In patients receiving low-dose UFH
subcutaneously, there is no contraindication to neuraxial
techniques, as the risk for developing spinal hematoma
appears to be minimal. In patients who are to receive
intraoperative anticoagulation with UFH, the UFH infusion
should be started at least 1 h after needle placement.
Indwelling catheters should be removed 2–4 h after dis-
continuation of the UFH infusion and only after the
patient’s coagulation status has been assessed [22].
Since UFH has a short half-life, reversal is not required in
most bleed episodes. The treatment of clinically severe UFH-
related bleeding includes anti-heparin therapy (protamine
sulfate), transfusion therapy, and supportive care. Protamine
dosing is dependent on timing of the last UFH dose. For
Table 1 Comparison of the pharmacologic features of heparin and its
derivatives
Features Heparin LMWH Fondaparinux
Source Biological Biological Synthetic
Molecular weight (Da) 15,000 5,000 1,500
Target Xa:IIa Xa [ IIa Xa
Bioavailability (%) 30 90 100
Half-life (h) 1 4 17
Renal excretion No Yes Yes
Protamine reversal Complete Partial None
Incidence of HIT (%) \5.0 \1.0 Case reports
Da Dalton, h hours, HIT heparin-induced thrombocytopenia
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immediate reversal (\30 min since the last UFH dose), 1 mg
of protamine is administered for every 100 U of UFH and a
follow up aPTT can evaluate the reversal response. When
UFH is given as a continuous IV infusion, only UFH deliv-
ered during the preceding 2–2.5 h should be included in the
calculation to determine the protamine dose. If the UFH dose
is unknown, protamine 50 mg can be administered slowly
over 10 min followed by serial measurements of aPTT.
Severe adverse reactions to protamine, such as hypotension
and bradycardia, are common. Reaction severity may be
reduced by slowing the administration over 1–3 min (max-
imum administration rate is 5 mg/min). Allergic responses
to protamine are more common in patients who have been
previously exposed to the drug for UFH neutralization, or
treated with protamine-containing insulin (neutral protamine
Hagedorn insulin), have undergone vasectomy, or have
hypersensitivity to fish. Patients at risk of developing anti-
protamine antibodies can be pretreated with corticosteroid
and anti-histamine medications [23–24].
Low Molecular Weight Heparins
Pharmacodynamics and Monitoring
LMWHs have increased bioavailability after subcutaneous
injection, renal clearance that is dose-independent, and a
longer half-life (17–21 h) when compared to UFH.
LMWHs are administered in fixed doses for thrombopro-
phylaxis, or in total body weight adjusted doses for thera-
peutic anticoagulation (Table 3) [5, 25].
With their predictable dose response (peak anti-Xa
activity occurring 3–5 h after injection) laboratory moni-
toring is usually not necessary. Anti-Xa monitoring is an
option in high-risk patient populations (renal insufficiency,
obesity, pregnancy, non-compliance) where dosing
adjustments may be required to tailor therapy. In these
cases anti-Xa plasma levels are drawn 4 h after adminis-
tration, and subsequent dosing adjusted to peak target
levels of 0.5–1.1 IU/mL [26, 27]. Anti-Xa tests should be
monitored and interpreted per the manufacturer of the
specific LMWH being used.
Clinical Indications
For medically ill and post-operative patients requiring
parenteral VTE prophylaxis, LMWHs have become a
suitable replacement for UFH [28, 29]. LMWHs require
fewer injections and produce fewer adverse events. In
hospitalized medical patients receiving thromboprophy-
laxis, LMWH was associated with a lower risk of deep vein
thrombosis (DVT), fewer injection site hematomas, and no
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LMWHs have largely replaced IV UFH in patients with
acute VTE who are able to continue therapy, unmonitored
in the ambulatory setting [31]. In ACS, patients with ST-
segment elevation myocardial infarction treated with
fibrinolysis and LMWH had a lower incidence of death or
non-fatal recurrent myocardial infarction but a higher rate
of major bleeding than those treated with fibrinolysis and
UFH [32]. Similarly, in unstable angina/non-ST-segment
elevation myocardial infarction, LMWH therapy reduced
the incidence of death, myocardial infarction, or urgent
revascularization when compared to UFH [33].
Complications and Reversal of Effect
Hemorrhage is the major complication of LMWH, with
some data supporting decreased rates of bleeding compared
to UFH. Rates of fatal bleeding are reported in 0–0.8 %
and major bleeding in 0–3 % of patients [16]. In the sur-
gical setting, peri-procedural thromboembolic risk assess-
ment, bleeding risk assessment, and physician preference
will play a role in determining whether LMWH prophy-
lactic dosing is continued or withheld. For patients
receiving therapeutic LMWH dosing, discontinuation
should be considered 12–24 h prior to procedure, or longer
in patients with renal dysfunction. Therapeutic doses of
LMWH should not be restarted for 24 h after a major
procedure or after neuraxial anesthesia [19, 32].
In the setting of overdose or life-threatening hemorrhage,
protamine is administered IV. Protamine does not fully
reverse LMWH but can neutralize the AT effect. Because
longer heparin chains bind to protamine, protamine com-
pletely reverses the anti-factor IIa activity of LMWH but
only reverses 60 % of the anti-factor Xa activity. If
immediate reversal is warranted within 8 h of LMWH
administration, a protamine dose of 1 mg neutralizes 100 U
anti-Xa or 1 mg of LMWH. If bleeding continues, a second
dose of 0.5 mg of protamine per 100 U anti-Xa may be
administered. Smaller protamine doses are required if the
LMWH administration interval is beyond 8 h [34, 35].
HIT and HIT with thrombosis (HITT) are immune-
mediated disorders that result from antibodies being
formed against the heparin–platelet factor IV complex. The
incidence of HITT in critically ill patients ranges from 1 to
5 % and is associated with the development of thrombo-
cytopenia and life-threatening thrombosis in approximately
30–50 % of HIT positive patients [36]. This immune-
mediated response typically occurs in patients exposed to
UFH or LMWH for 5–7 days, or sooner if the patient was
previously exposed. A 50 % decrease in platelet count
occurring 4–10 days after the initiation of UFH or LMWH
therapy or formation of a new thrombus while anticoagu-
lated may be indicative of HIT. Platelet counts should be
measured prior to the initiation of UFH or LMWH and
monitored every other day for the first 4–10 days of ther-
apy. The incidence of HIT is approximately one-tenth
lower with LMWH than with UFH [37]. In the setting of a
HIT allergy or if positive HIT antibodies have been
detected, LMWH cannot be used due to cross reactivity
between glycosaminoglycans. Direct thrombin inhibitors
(DTIs) are the treatment of choice for patients with HIT or
HITT [38, 39].
Osteoporosis reportedly occurs less frequently in
patients treated with LMWH as compared to UFH, and it
typically is associated with long-term therapy [6••].
Fondaparinux
Pharmacodynamics and Monitoring
After subcutaneous administration, fondaparinux is rapidly
and completely absorbed, exhibiting a half-life of 17–21 h
in patients with normal renal function [6••]. Fondaparinux
is excreted primarily unchanged in the urine with clearance
reduced in patients with renal impairment. Similar to
LMWH, with predictable pharmacokinetics, monitoring
anti-Xa levels is not recommended during fondaparinux
administration.
Clinical Indication
Fondaparinux has been proven to be at least as safe and
effective as treatment of DVT and pulmonary embolism
(PE) as LMWH and UFH, respectively [40, 41] (Table 4).
Fondaparinux has been studied extensively for thrombo-
prophylaxis in medically ill and surgical patients [42, 43].
In three trials fondaparinux showed superior efficacy in
reducing VTE in patients undergoing knee arthroplasty, hip
arthroplasty, and hip fracture surgery [44–46]. In a com-
bined analysis, the overall incidence of major bleeding was
statistically higher with fondaparinux (2.7 %) compared
with LMWH (1.7 %) [47]. However, the incidence of
clinically relevant bleeding, as defined as bleeding leading
to death, reoperation, or occurring in a critical organ, did
not differ between the agents. The differences in efficacy
and safety outcomes could be related to dosing as well as
the timing of peri-operative drug administration. The
administration of fondaparinux given less than 6 h after
surgery has been associated with an increased frequency of
major bleeding [48]. Holding therapy for at least 6 h post-
procedure may be recommended in patients at risk of
bleeding. Fondaparinux may be a potential option for
thromboprophylaxis in the setting of an HIT allergy but no
conclusive data is available [49]. While fondaparinux has
been studied in ACS, it has not received Food and Drug
Administration (FDA) approval.
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Complications and Reversal of Effect
Fondaparinux is contraindicated in patients with severe renal
impairment (calculated creatinine clearance less than 30 mL/
min). Fondaparinux should not be used for VTE prophylaxis in
patients weighing less than 50 kg. Fondaparinux reversal is
further complicated by its prolonged half-life [50]. While no
specific antidote exists for the fondaparinux-related hemor-
rhage, recombinant activated factor VII (rFVIIa) administration
can normalize coagulation times and thrombin generation [51].
Direct Thrombin Inhibitors (DTIs)
DTIs exert their antithrombotic effect through direct,
selective, and reversible binding to the active site of
thrombin. This leads to inhibition of thrombin-catalyzed or
-induced reactions, including fibrin formation, activation of
coagulant factors V, VIII, XIII, protein C, and platelet
aggregation. The hirudin analogs, desirudin and bivaliru-
din, and argatroban are three currently approved DTIs [52].
Pharmacology, Pharmacodynamics, and Monitoring
Bivalirudin and desirudin are synthetic analogs of r-hirudin
that exert anticoagulant activity by reversible binding at the
enzymatic catalytic site and the anion binding site of
thrombin. Argatroban, derived from the amino acid argi-
nine, is a small synthetic thrombin inhibitor that reversibly
binds non-covalently to thrombin active site [52].
The DTIs differ in their pharmacokinetic parameters
(Table 5) [52]. Bivalirudin has the shortest half-life, making
it a particularly useful agent in the procedural or peri-pro-
cedural period. DTI selection often depends on patient-
specific characteristics such as age, compromised cardiac
function, hemodynamic instability, and hepatic or renal
dysfunction [52, 53]. Critically ill patients typically require
lower infusion rates than recommended by the manufacturer
due to the presence of comorbidities and organ dysfunction.
DTIs are monitored using aPTT, with a goal of 1.5–3 times
control or baseline (argatroban), 1.5–2.5 times control
(bivalirudin) (Table 6). Desirudin does not need routine
coagulation monitoring. The aPTT level should be measured
every 6 h until the patient has sustainable therapeutic levels,
then the frequency of monitoring can be extended. Because
of inconsistencies in aPTT measurements, the plasma dilu-
ted thrombin time has shown to be an alternative to for
monitoring DTI levels, especially in patients with lupus
inhibitors or low levels of vitamin K-dependent factors [54].
Clinical Indications
DTIs can be used as an alternative anticoagulant to UFH
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administration significantly reduced the rates of thrombo-
embolic complications in patients with HIT [56]. Biva-
lirudin has been safely used in critically ill and HIT
patients [57]. Argatroban and bivalirudin are indicated as
an anticoagulant for thrombosis prevention in patients
undergoing percutaneous coronary intervention (PCI).
Bivalirudin is indicated for use as an anticoagulant in the
treatment of patients with moderate to high-risk ACS,
Table 5 Pharmacokinetic and pharmacodynamic properties of DTIs
Feature Desirudin Argatroban Bivalirudin
Molecular weight (Da) 6963 526 2180
FDA-approved
indication
Prophylaxis of DVT in patients
undergoing elective hip replacement
surgery
Management of HIT, or use in
patients with HIT who are
undergoing PCI
Use in patients with or at risk for HIT




Elimination half-life SC = 120 min
IV = 60 min







Not required aPTT, ECT aPTT, ACT, ECT
Target range n/a aPTT: 1.5–39 control aPTT: 1.5–2.59 control
Effects on INR Minimal Moderate to clinically significant Minimal to moderate
Da Dalton, FDA Food and Drug Administration, HIT heparin-induced thrombocytopenia, HITTS HIT with thrombosis syndrome, PCI percu-
taneous coronary intervention, SC subcutaneous, IV intravenous, aPTT activated partial thromboplastin time, ECT ecarin clotting time, ACT
activated clotting time, INR international normalized ratio
Table 6 Clinical uses of DTIs
Drugs Indications Dosing, timing, duration Monitoring Precautions
Bivalirudin
(AngiomaxTM)
PCI (with or without
glycoprotein IIB/IIIA
inhibitor)
0.75 mg/kg IV bolus dose, followed by an infusion


















Recent major, spinal or
ophthalmologic
surgery












CrCl less than 30 mL/min, a reduction of initial
infusion rate to 1 mg/kg/h should be considered;
no bolus dose reduction is necessary




0.15–0.2 mg/kg/h, titration to aPTT 1.5–2.5 times
control
Argatroban Treatment and prophylaxis
of HITT
0.5–1.2 lg/kg/min continuous IV infusion to start
titration to goal aPTT of 1.5–3 times baseline
Begin VKA therapy, measure INR daily. Stop
argatroban when INR [4. Repeat INR in 4–6 h,
if INR is below desired range then resume
argatroban infusion
PCI Bolus: 350 lg/kg
Initial infusion: 25 lg/kg/min maintain ACT
greater than 300 seconds




15 mg SC every 12 h given 5–15 min prior to
surgery but before induction of regional block
anesthesia (if used)
PCI percutaneous coronary intervention, IV intravenous, CrCl creatinine clearance using the Cockroft–Gault Equation, CBC complete blood
count, aPTT activated partial thromboplastin time, ACT activated clotting time, PT prothrombin time, INR international normalized ratio, ECG
echocardiogram, HITT heparin-induced thrombocytopenia and thrombosis, VKA vitamin K antagonist, ACS acute coronary syndrome
a Indicates off label use of medication
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unstable angina/non-ST-segment elevation myocardial
infarction who are undergoing early invasive management,
and in patients undergoing PCI (Table 6) [5].
Complications and Reversal of Effect
Hemorrhage is the most common complication with DTIs
and no specific reversal agent is available. Anecdotally,
rFVIIa has been reported to be useful and could be con-
sidered for immediate treatment of life-threatening hem-
orrhage [58]. DTIs can produce a misleading elevation in
the international normalized ratio (INR), complicating the
transition to warfarin in HIT. A clinical strategy to bridge
safely and effectively should be undertaken in order to
avoid thrombosis or bleeding. Steps in a bridging strategy
include determining a baseline INR while on the DTI,
identifying a target INR level (desired 1.5–2-point
increase) while considering the INR elevation induced by
the DTI, once INR goal is reached withhold the DTI for
4–8 h, and recheck the INR and aPTT. If the INR is 2–3
with an aPTT close to baseline after the clinician accounts
for the independent warfarin-related elevation in the aPTT,
the DTI can be discontinued [49].
Oral Anticoagulants–Vitamin K Antagonists
Vitamin K antagonists (VKAs) produce their anticoagulant
effect by inhibiting vitamin K epoxy reductase, which is
required for the conversion of vitamin K to its active form
vitamin KH2. Vitamin K dependant proteins such as clot-
ting factors II, VII, IX, and X require c-carboxylation by
vitamin KH2 for biological activity [59•].
The relationship between the dose of warfarin and the
response varies between patients and is modified by genetic
and environmental factors (dietary intake, drug interac-
tions, critical illness, etc.) that can influence the absorption
of warfarin, its pharmacokinetics, and its pharmacody-
namics [59•, 60•, 61–63].
A wide dosing range is required to maintain a thera-
peutic INR with relatively low doses often required for the
elderly and patients with underlying comorbidities.
Nomogram based dosing is considered safer and more
effective at reaching targeting INR goals [64]. Larger ini-
tial doses suppress proteins C and S, producing a hyper-
coagulable response and are associated with over-
anticoagulation and higher rates of bleeding.
Clinical Indications
Warfarin is effective for the primary and secondary pre-
vention of VTE, for the prevention of systemic embolism
in patients with prosthetic heart valves or AF, for the pri-
mary prevention of acute myocardial infarction in high-risk
men, and for the prevention of stroke, recurrent infarction,
or death in patients with acute myocardial infarction
(Table 7) [59•, 65–68].
Complications and Reversal of Effect
Bleeding is a major concern with warfarin therapy due to
the influence of environmental factors and drug interactions
in the setting of a narrow therapeutic index. Treatment with
VKA increases the risk of major bleeding by 0.3–0.5 % per
year and the risk of intracranial hemorrhage by approxi-
mately 0.2 % per year compared to controls. The most
important risk factors for hemorrhage in VKA therapy
include: intensity of anticoagulant effect, time within ther-
apeutic range, and patient characteristics. Higher goal INRs
(INR [3) have been directly associated with increased rates
of hemorrhage, and patients at high risk of bleeds may
benefit from lower target goals [59•, 60•].
Reversal of warfarin’s anticoagulant effect requires with-
holding therapy. The duration of effect can last up to several
days in the absence of reversal agent administration. In
patients with clinically significant bleeding, the administra-
tion of vitamin K is crucial to reversing the anticoagulant
effects of VKAs. In the setting of an INR between 4.5 and 10
and no significant bleeding, the next doses of warfarin should
be held and the INR evaluated [60•]. When the INR is [10 and
the patient has no significant signs of bleeding, the guidelines
recommend holding warfarin and giving oral vitamin K. In the
setting of serious/life-threatening bleeding at any INR, war-
farin should be held and vitamin K 10 mg by slow IV infusion
is recommended. Higher doses of vitamin K are effective but
may lead to VKA resistance for more than a week. Vitamin K
may be given orally or parenterally, with the IV route pro-
viding a more rapid response. The intramuscular or subcuta-
neous routes are not recommended in the critically ill due to
unpredictable absorption. In cases where immediate reversal
of the INR is necessary the supplementation of clotting factors
with fresh frozen plasma (FFP), or prothrombin complex
concentrate (PCC) are more effective. PCCs contain more
clotting factors in a smaller volume and have been shown to be
more effective in the reversal of warfarin therapy. Recombi-
nant factor VIIa may be of benefit in patients with refractory
bleeding in the setting of elevated INRs [60•, 61–69].
Non-hemorrhagic adverse events of warfarin include
acute skin necrosis and limb gangrene; these uncommon
complications are observed on the third to eighth day of
therapy. Skin necrosis is caused by extensive thrombosis of
the venules and capillaries within the subcutaneous fat,
typically associated with protein C deficiencies. Limb
gangrene, however, is due to massive outflow obstruction
of the venous circulation of the limb, and can be seen in
HIT patients treated with warfarin without adequate initial
bridging with a DTI [59•].
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Patients on VKAs requiring surgery should hold therapy
approximately 5 days prior to the intervention. Depending
upon the patient’s history and risk of VTE or arterial
thromboembolism, bridging with LMWH or UFH may be
warranted. VKA may be resumed 12–24 h post-surgery,
depending on bleeding risk and hemostasis. Assessment of
the INR should be undertaken before neuraxial anesthesia is
performed. For patients with an indwelling catheter who are
receiving warfarin, the catheter should be removed when
the INR is less than 1.5. Patients with a low risk of bleeding
may undergo surgery with an INR of 1.3–1.5 [19–21, 70].
Target-Specific Oral Anticoagulants
Dabigatran, rivaroxaban, and apixaban are novel oral
anticoagulants that offer major advantages over current
agents. They have rapid onset and more predictable anti-
coagulants response that eliminates the need for monitor-
ing. Clinical trials have been completed with all three
agents in the prevention and treatment of the three leading
causes of cardiovascular death: myocardial infarction,
stroke, and VTE. Novel agents have shown reduced or
similar rates of thrombosis, major bleeding, and adverse
events when weighed against either LMWH or warfarin.
Pharmacology, Pharmacodynamics, and Monitoring
Dabigatran etexilate mesylate is a prodrug. After oral
administration, non-specific plasma and hepatic esterases
hydrolyze the compound into the active anticoagulant,
dabigatran [71]. Dabigatran is DTI that exerts its action
through reversible, competitive binding to the active site on
Table 7 Clinical uses of warfarin




Treatment of VTE Initial dosing: 2.5–10 mg every 24 h
(see precautions) titrated to range







Lower initial dosing (less than 5 mg may be
warranted in patients who are debilitated, are
malnourished, have congestive heart failure,
have liver disease, have had recent major
surgery, or are taking medications known to
increase sensitivity to warfarin)
Cerebrovascular disease
Coronary disease
CYP2C9 and VKORC1 genetic variation






Conditions that increase risk of hemorrhage,
necrosis, and/or gangrene, pre-existing
Congestive heart failure
Sever diabetes
Excessive dietary vitamin K





Infectious diseases or disturbances of intestinal





Atrial fibrillation Initial dosing: 2.5–10 mg every 24 h
(see precautions) titrated to range
INR: 2.0–3.0; target of 2.5
Post-MI Initial dosing: 2.5–10 mg every 24 h
(see precautions) titrated to range




Initial dosing: 2.5–5 mg every 24 h
(see precautions) titrated to range




Initial dosing: 2.5–5 mg every 24 h
(see precautions) titrated to range
INR: 2.5–3.5; target of 3.0
Mechanical valve
in both the atrial
and mitral
position
Initial dosing: 2.5–5 mg every 24 h
(see precautions) titrated to target




Initial dosing: 2.5–5 mg every 24 h
(see precautions) titrated to target
INR: 2.0–3.0; target of 2.5 for
3 months
VTE venous thromboembolism, h hours, INR international normalized ratio, CBC complete blood count, PT prothrombin time, MI myocardial
infarction
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thrombin. Furthermore, dabigatran indirectly exerts an
anti-platelet effect by reducing thrombin’s impact on pro-
moting platelet activation and aggregation [72].
Dabigatran is eliminated through renal filtration with up
to 80 % of the dose excreted unchanged in urine (Table 8).
Dabigatran’s mean terminal elimination half-life is pro-
longed in patients with severe renal dysfunction. There is
no antidote available to reverse or attenuate dabigatran’s
anticoagulant effect [72].
Rivaroxaban is an oral, highly selective, direct, com-
petitive inhibitor of factor Xa [73]. Inhibition of factor Xa
leads to interruption of the both intrinsic and extrinsic
coagulation pathways, thus preventing thrombin generation
and subsequent thrombus formation. Rivaroxaban’s inhi-
bition of both free and fibrin-bound factor Xa differentiates
its action from LMWH or fondaparinux. Rivaroxaban
exerts minimal effect on platelet function.
In patients with CrCl 15–30 mL/min, the dabigatran
dose should be reduced to 75 mg twice daily [71]. The
manufacturer does not recommend the use of rivaroxaban
in patients with an estimated creatinine clearance less than
15 mL/min [74].
Clinical Indications
While dabigatran has been compared with enoxaparin for
VTE prophylaxis, and with warfarin in acute VTE treat-
ment and secondary prevention, it only has FDA approval
for stroke prevention in AF (Table 9).
RE-LY was a non-inferiority trial designed to deter-
mine the long-term safety and efficacy of dabigatran
administered twice daily as compared to warfarin (INR
goal 2.0–3.0) in patients with non-valvular AF [75].
Patients were required to have at least one addition
thromboembolism risk factor. The primary efficacy out-
come was defined as the occurrence of stroke or systemic
embolism. The dabigatran 150 mg twice daily regimen
was statistically superior to warfarin in reducing the rate
of stroke and systemic embolism, 1.11 % per year versus
1.69 % per year, respectively (p \ 0.001). As any other
anticoagulant, bleeding is the major adverse event. In Re-
LY trial, the primary safety outcome was major bleeding.
There was no difference in the rate of major bleeding in
the dabigatran 150 mg group compared with the warfarin
group.
Rivaroxaban has been studied in a large clinical trial
program and has FDA approval for a variety of indications.
The orthopedic surgery program compared rivaroxaban to
enoxaparin for VTE prevention in patients undergoing total
hip and total knee arthroplasty [76–79]. The primary effi-
cacy endpoint was total VTE, the composite of any DVT,
non-fatal PE, and all-cause mortality. In the RECORD1, -2,
-3 and -4 studies rivaroxaban 10 mg daily was superior to
enoxaparin and associated with a similar safety profile.
Rivaroxaban has been evaluated for stroke prevention in
patients with non-valvular AF [80]. In the ROCKET-AF
trial rivaroxaban 20 mg once daily was non-inferior to
warfarin in reducing all-cause stroke and non-central ner-
vous system embolism in with a similar rate of major
bleeding. Rivaroxaban has been studied for the acute DVT
and PE treatment and for the long-term secondary pre-
vention of recurrent VTE [81, 82]. The EINSTEIN-DVT
study found rivaroxaban 15 mg twice daily for 3 weeks
followed by 20 mg daily was non-inferior to enoxaparin
followed by a VKA in the prevention or recurrent VTE
[81]. In the EINSTEIN-Extension trial, rivaroxaban 20 mg
daily extended for an additional 6–12 months significantly
reduced recurrent VTE without an increase in major or
clinically relevant non-major bleeding when compared
with placebo. In EINSTEIN-PE rivaroxaban was found to
be non-inferior to enoxaparin combined with a VKA in the
prevention of recurrent VTE while providing a significant
reduction in major bleeding [82].







b Cytochrome (CYP) P450 3A4




Features Dabigatran etexilate Rivaroxaban Apixaban
Target Thrombin Factor Xa Factor Xa
Prodrug Yes No No
Dosing Fixed Fixed Fixed
Bioavailability (%) 6 80 90
Food effects Delay Tmax 2–4 h Delays Tmax Not reported
Half-life (h) 12–17 5–9 12
Renal excretion (%) 80 65 25
Coagulation monitoring No No No
Antidote None None None
Interactions P-gp inhibitorsa Combined P-gp and
CYP3A4 inhibitorsb
Potent 3CYP3A4 inhibitorsb
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While apixaban has been evaluated in thromboprophy-
laxis following orthopedic surgery, secondary prevention
of VTE, and ACSs, its sole FDA approval is in stroke
prevention in AF [83•].
In the ARISTOTLE trial, investigators compared apix-
aban 5 mg twice daily with warfarin titrated to a goal INR
of 2–3 [84]. The primary outcome, a composite of stroke
and systemic embolism, occurred significantly less fre-
quently in the apixaban patients compared to the warfarin
patients. Bleeding was significantly less frequent in the
apixaban patients compared to the warfarin patients across
several bleeding definitions tested.
Complications and Reversal of Effect
The most common adverse events reported with dabigatran
include dyspepsia, dizziness, headache, dyspnea, and
shortness of breath. Abdominal pain and gastritis-like
symptoms may be related to the capsule formulation which
can be combated by taking the medication with food [83•].
There are no specific coagulation assays for laboratory
monitoring of novel oral anticoagulants. Thrombin time
and aPTT can be used to detect the presence of dabigatran
in the plasma [85]. Similarly, rivaroxaban and apixaban
prolong prothrombin time and aPTT. The role of other
newer assays (Heptest, prothrombinase-induced clotting
time, Anti-FXa chromogenic assays) have yet to be
established.
Currently, there is no antidote available to reverse da-
bigatran, rivaroxaban, or apixaban. In the event of over-
dose, the early use of activated charcoal is recommended
[83•]. Cessation of dabigatran, rivaroxaban, or apixaban
therapy may be sufficient to reverse any excessive antico-
agulant effect due to their short half-lives. While dialysis,
for 2–3 h removes up 60 % of dabigatran, it has no impact
on rivaroxaban or apixaban [85].
Limited data exists for treatment of life-threatening
bleeding produced by novel anticoagulants. Recent trials
have suggested PCCs or rFVIIa may offer benefit by nor-
malizing coagulation parameters [74, 86•, 87]. Their
evaluation, use, and role in the clinical setting are still
required. In the event of bleeding symptomatic treatment of
the hemorrhage should be initiated [83•].
For the novel agents, confusion and debate may ensue if
prescribed in patient populations, such as those with
pregnancy, mechanical heart valves, and thrombophilias,
where little study data and clinical experience exists.
Similarly, surgical and invasive procedures add additional
levels of complexity where therapy may be continued,
interrupted, or replaced with short-term parenteral or
‘bridge’ therapy.
Table 9 Clinical uses of target-specific oral anticoagulants












P-gp inducers and inhibitors
CrCl 15–30 mL/min: 75 mg twice
daily
Rivaroxaban (Xarelto) Stroke prophylaxis
in non-valvular AF
CrCl [50 mL/min: 20 mg once





CrCl \15 mL/min in non-
valvular AF
CrCl \30 mL/min in treatment
or prevention of DVT, PE
P-gp inducers or inhibitors
CYP3A4 inducers or inhibitors
Pregnancy
CrCl 15–50 mL/min: 15 mg once
daily with the evening meal
Treatment of DVT
or PE
15 mg twice daily with food for
21 days then 20 mg daily with









10 mg once daily for 35 days (hip
replacement) or 12 days (knee
replacement)




5 mg twice daily or 2.5 mg twice
daily in patients with at least
two of: age [80 years, body




CrCl creatinine clearance, DVT deep vein thrombosis, PE pulmonary embolism
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Conclusions
UFH, LMWHs, fondaparinux, DTIs, and warfarin have been
studied and employed extensively for prevention and treat-
ment of thrombosis. Novel oral anticoagulants have
emerged from clinical development and are expected to
replace older agents with their ease of use and more favor-
able pharmacodynamic profiles. Hemorrhage is the main
concerning adverse event with all anticoagulants. With their
ubiquitous use, it becomes important for clinicians to have a
sound understanding of anticoagulant pharmacology, dos-
ing, monitoring, and toxicity. Working knowledge becomes
crucial for intercepting and averting problems.
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